Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer | |
Ma,Liying1,2,3; Bian,Xing1,2,3; Lin,Wenchu1,2 | |
刊名 | Journal of Experimental & Clinical Cancer Research |
2021-01-05 | |
卷号 | 40 |
DOI | 10.1186/s13046-020-01805-6 |
通讯作者 | Lin,Wenchu(wenchu@hmfl.ac.cn) |
英文摘要 | An amendment to this paper has been published and can be accessed via the original article. |
语种 | 英语 |
出版者 | BioMed Central |
WOS记录号 | BMC:10.1186/S13046-020-01805-6 |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/125701] |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Lin,Wenchu |
作者单位 | 1.Chinese Academy of Sciences; Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science 2.Chinese Academy of Sciences; High Magnetic Field Laboratory 3.University of Science and Technology of China |
推荐引用方式 GB/T 7714 | Ma,Liying,Bian,Xing,Lin,Wenchu. Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer[J]. Journal of Experimental & Clinical Cancer Research,2021,40. |
APA | Ma,Liying,Bian,Xing,&Lin,Wenchu.(2021).Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.Journal of Experimental & Clinical Cancer Research,40. |
MLA | Ma,Liying,et al."Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer".Journal of Experimental & Clinical Cancer Research 40(2021). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论